Wanhong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wanhong Chen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Hong Li
CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
14 shared publications - Jianyu Yang
Shanghai Jiao Tong University 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications - Junfeng Zhang
Shanghai Jiao Tong University 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications - Lingye Tao
Shanghai Jiao Tong University 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications - Linli Yao
Shanghai Jiao Tong University 3 State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications - Minwei Yang
Shanghai Jiao Tong University 1 Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine Shanghai, China
14 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S3. Analysis of bulk RNA-seq data on metastatic tumor tissues of anti-PD1 monotherapy, anti-LAG3 monotherapy and anti-PD1 plus anti-LAG3 combined therapy.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S3. Analysis of bulk RNA-seq data on metastatic tumor tissues of anti-PD1 monotherapy, anti-LAG3 monotherapy and anti-PD1 plus anti-LAG3 combined therapy.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Signature genes of M1 and M2 macrophages derived from PMID: 33545035.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Signature genes of M1 and M2 macrophages derived from PMID: 33545035.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Signature genes of all ductal subclusters.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Signature genes of all ductal subclusters.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
GSEA results for all ductal subclusters using genesets collected from published articles.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
GSEA results for all ductal subclusters using genesets collected from published articles.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Cell markers for celltype annotation.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Cell markers for celltype annotation.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Clinical information of patients with metastatic PDAC.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Clinical information of patients with metastatic PDAC.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
GSEA results for all ductal subclusters using Gene Ontology (GO) terms.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
GSEA results for all ductal subclusters using Gene Ontology (GO) terms.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S4. Association between H2AFZ expression and genomic mutations in PDAC.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S4. Association between H2AFZ expression and genomic mutations in PDAC.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S2. Cellular compositions of myeloid and T cell subclusters between hepatic metastases and healthy livers.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S2. Cellular compositions of myeloid and T cell subclusters between hepatic metastases and healthy livers.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S1. Functional interrogation of ductal subclusters and the prognostic value of PFN1.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma
Figure S1. Functional interrogation of ductal subclusters and the prognostic value of PFN1.